Expanding Interdisciplinary Translational Project Infrastructure.
Lead Research Organisation:
University of Birmingham
Department Name: UNLISTED
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Technical Summary
The Confidence in Concept scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach –– before seeking more substantive funding. It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.
Organisations
People |
ORCID iD |
| Jon Frampton (Principal Investigator) |
Publications
Browning DF
(2015)
Cross-species chimeras reveal BamA POTRA and ß-barrel domains must be fine-tuned for efficient OMP insertion.
in Molecular microbiology
Browning DF
(2015)
Cross-species chimeras reveal BamA POTRA and ß-barrel domains must be fine-tuned for efficient OMP insertion.
in Molecular microbiology
Chung BK
(2017)
Phenotyping and auto-antibody production by liver-infiltrating B cells in primary sclerosing cholangitis and primary biliary cholangitis.
in Journal of autoimmunity
Diviani D
(2016)
Small-Molecule Protein-Protein Interaction Inhibitor of Oncogenic Rho Signaling.
in Cell chemical biology
Diviani D
(2016)
Small-Molecule Protein-Protein Interaction Inhibitor of Oncogenic Rho Signaling.
in Cell chemical biology
Duprey JHA
(2018)
Rationalisation of a mechanism for sensing single point variants in target DNA using anthracene-tagged base discriminating probes.
in Organic & biomolecular chemistry
Horniblow RD
(2015)
Alginate-Iron Speciation and Its Effect on In Vitro Cellular Iron Metabolism.
in PloS one
Triantafyllou E
(2018)
MerTK expressing hepatic macrophages promote the resolution of inflammation in acute liver failure.
in Gut
| Description | BBSRC PhD studentship (Dr Chris Tselepis, CiC: Using alginates for the prevention and treatment of bowel disease) |
| Amount | £60,000 (GBP) |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | Cell Therapy Catapult (Dr Steven Lee, CiC: Targeting the tumour vasculature with engineered T-cells) |
| Amount | £880,772 (GBP) |
| Organisation | Cell Therapy Catapult |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | Development of a synthetic bioactivated membrane dressing |
| Amount | £1,583,277 (GBP) |
| Funding ID | 102569/Z/13/Z |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 02/2015 |
| End | 12/2019 |
| Description | Experimental Challenge Grant- (Tim Wells and Ian Henderson, CiC: Developing a diagnostic test and novel treatment methods for patients with bronchiectasis and inhibitory antibodies) |
| Amount | £671,596 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | MRC DPFS (Professor Ann Logan, CiC: Development of a synthetic anti-scarring membrane dressing for corneal burns) |
| Amount | £2,357,078 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Title | ANTI-CANCER COMPOSITION COMPRISING ALGINATE |
| Description | The present invention relates to a biologically acceptable composition for the prophylaxis and/or treatment of colorectal cancer comprising an iron chelator, wherein the composition is adapted for the selective targeting of the iron chelator to the colon. |
| IP Reference | WO2011051665 |
| Protection | Patent application published |
| Year Protection Granted | 2011 |
| Licensed | Commercial In Confidence |
| Impact | Priorty no. GB0918722, 26/10/2009 |
| Title | ANTIBODIES AND RELATED MOLECULES AND USES THEREOF |
| Description | The present invention relates to an isolated antibody, which selectively binds to CLEC14A, wherein said antibody (a) comprises at least one heavy chain variable region that comprises three CDRs and at least one light chain variable region that comprises three CDRs, wherein said heavy chain variable region comprises:(i) a variable heavy (VH) CDR1 that has the amino acid sequence of SEQ ID NO. 105, preferably of SEQ ID NO: 2 or 42; (ii) a VH CDR2 that has the amino acid sequence of SEQ ID NO. 106, preferably of SEQ ID NO: 3 or 43; and/or (iii) a VH CDR3 that has the amino acid sequence of SEQ ID NO. 107, preferably of SEQ ID NO: 4 or 44; and/or wherein said light chain variable region comprises: (iv) a variable light (VL) CDR1 that has the amino acid sequence of SEQ ID NO. 108, preferably of SEQ ID NO: 6 or 46; (v) a VL CDR2 that has the amino acid sequence of SEQ ID NO. 109, preferably of SEQ ID NO: 7 or 47; and/or (vi) a VL CDR3 that has the amino acid sequence of SEQ ID NO. 1 10, preferably of SEQ ID NO: 8 or 48; or (b) comprises at least one heavy chain variable region that comprises three CDRs and at least one light chain variable region that comprises three CDRs, wherein said heavy chain variable region comprises: (i) a variable heavy (VH) CDR1 that has the amino acid sequence of SEQ ID NO: 22; (ii) a VH CDR2 that has the amino acid sequence of SEQ ID NO: 23; and/or (iii) a VH CDR3 that has the amino acid sequence of SEQ ID NO: 24; and/or wherein said light chain variable region comprises: (iv) a variable light (VL) CDR1 that has the amino acid sequence of SEQ ID NO: 26; (v) a VL CDR2 that has the amino acid sequence of SEQ ID NO: 27; and/or (vi) a VL CDR3 that has the amino acid sequence of SEQ ID NO: 28; or (c) is an antibody which can compete with antibody (a) or (b) for binding to CLEC14A. The invention further provides chimeric antigen receptors, nucleic acid molecules encoding the antibodies of the invention or the chimeric antigen receptors, vectors, cells and methods/uses of the antibodies and chimeric antigen receptors. |
| IP Reference | WO2017158339 |
| Protection | Patent application published |
| Year Protection Granted | 2017 |
| Licensed | Commercial In Confidence |
| Impact | n/a |
| Title | CELL DELIVERY MEDIUM |
| Description | The invention provides a cell delivery medium comprising a liquid phase, wherein the liquid phase comprises (i) one or more cells suspended within the liquid phase and (ii) a plurality of polymer gel particulates. Methods of producing the cell delivery systems are also provided. |
| IP Reference | WO2014140549 |
| Protection | Patent application published |
| Year Protection Granted | 2014 |
| Licensed | Commercial In Confidence |
| Impact | EP2968405, 20/01/2016 US2016045553, 18/02/2016 |
| Title | CHIMERIC ANTIGEN RECEPTOR |
| Description | The present invention is directed to a nucleic acid molecule comprising a polynucleotide sequence encoding a chimeric antigen receptor comprising (a) an anti-CLEC14A binding domain, (b) a transmembrane domain and (c) an intracellular signalling domain; wherein said anti-CLEC14A binding domain is capable of binding to the C- type lectin domain of CLEC14A. The invention further provides a chimeric antigen receptor encoded by the nucleic acid molecule, a vector comprising the nucleic acid molecule, a cell comprising the nucleic acid molecule, vector or CAR and the therapeutic use of the nucleic acid, vector or cell, particularly in treating CLEC14A expressing conditions. |
| IP Reference | WO2017158337 |
| Protection | Patent application published |
| Year Protection Granted | 2017 |
| Licensed | Commercial In Confidence |
| Impact | n/a |
| Title | DRESSING |
| Description | The invention relates to a surgical or wound dressing comprising a sheet of gellan gum and an antifibrotic agent. Methods of producing dressings comprising gellan gums and biologically active agents area also produced. |
| IP Reference | WO2016113550 |
| Protection | Patent application published |
| Year Protection Granted | 2016 |
| Licensed | Commercial In Confidence |
| Impact | GB201500430, 12/01/2015 |
| Company Name | Chimeric Therapeutics Ltd |
| Description | The Cell Therapy Catapult, the UK organisation dedicated to the growth of the UK cell and gene therapy industry by bridging the gap between scientific research and commercialisation, the University of Birmingham and Cancer Research Technology, the commercialisation arm of Cancer Research UK, announces today the launch of a collaboration to develop a new immuno-oncology cellular therapy based on gene modifying T cells to target solid tumours. The project is aimed at translating an academic discovery programme funded by Cancer Research UK and developed by Dr Steven Lee and Prof Roy Bicknell at the University of Birmingham into a commercially viable cell therapy. The collaborating partners have launched a new company, Chimeric Therapeutics Ltd. This new company will hold all future IP rights to the resultant discoveries. |
| Year Established | 2015 |
| Impact | The project is based on a new generation chimeric antigen receptor T-Cell (CAR-T) immuno-oncology therapy for solid tumours. This involves directing the CAR-T cell towards a new, highly specific marker of tumour angiogenesis, CLEC14a. This therapy will act as a vasculature disruptive agent compromising oxygen supply to the tumours and inhibiting tumour growth. The technology is currently undergoing the final stages of preclinical development, and is planned to enter into clinical trials soon after. The Cell Therapy Catapult will specifically be involved in the project to accelerate the translation of the academic discoveries made in Birmingham with Cancer Research Technology around CAR-T immunotherapies for solid tumours and the CLEC14a target towards a commercially available cell therapy. Immunotherapy is an exciting area in cancer treatment and this technology could provide a powerful route to harness the power of the immune system to block the development of blood vessels, and stop tumours growing. |
| Website | http://www.checkcompany.co.uk/company/09842382/CHIMERIC-THERAPEUTICS-LIMITED |
| Description | ARVO 2014 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | Yes |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Lots of discussion about my presentation, including critique of the work, and discussion about other avenues for research. I have revised some experimental techniques to be encompassed in more recent research work |
| Year(s) Of Engagement Activity | 2014 |
| Description | ARVO 2015 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Poster presentation of research outputs at ARVO 2015 |
| Year(s) Of Engagement Activity | 2015 |
| Description | Attendance at an International ophthalmology conference: ARVO |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Research presentation to the largest audience of ophthalmologists in the world |
| Year(s) Of Engagement Activity | 2018,2019 |
| Description | Attendence at international conference ARVO 2016 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Oral and poster presentations |
| Year(s) Of Engagement Activity | 2016 |
| Description | Attendence at international conference ARVO 2017 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Oral and poster presentations of our research outcomes. |
| Year(s) Of Engagement Activity | 2017 |
| Description | HRH Prince Harry visit |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | Prince harry visited the Scar Foundation centre at Birmingham University Hospital and met the research team in our research laboratories. |
| Year(s) Of Engagement Activity | 2019 |
| Description | Ophthalmic Research Group |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Type Of Presentation | Keynote/Invited Speaker |
| Geographic Reach | Local |
| Primary Audience | Health professionals |
| Results and Impact | Approximately 20 ophthalmic consultants and specialist trainees with an interest in research outputs, and a few laboratory scientists attended this talk. My presentation was the only item onthe programme, as an invited talk. . |
| Year(s) Of Engagement Activity | 2013 |
| Description | Participation in Brain Awareness Week |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | As part of Brain Awareness Week (http://www.dana.org/BAW/) (March 13-19) we had displays at the ThinkTank in Birmingham, a series of open lectures at the University of Birmingham and a Café Scientifique in a Birmingham pub. |
| Year(s) Of Engagement Activity | 2017 |
| URL | http://www.dana.org/BAW/ |
| Description | Participation in Brain Awareness Week |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | Demonstrations of corneal dressing to public in Brain Awareness Week |
| Year(s) Of Engagement Activity | 2019 |
| Description | RCOphth/MRC John Lee Fellowship fundraising evening/quiz night |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | I gave a presentation of the research work I am undertaking, prompting discussion and questions from the audience. I was asked to undertake an interview for the RCOphth magazine, to highlight my research activities. |
| Year(s) Of Engagement Activity | 2014 |
| Description | Seminar at the Centre for Brain Repair, University of Cambridge |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Postgraduate students |
| Results and Impact | Research seminar |
| Year(s) Of Engagement Activity | 2018 |